- Book学术

发布求助

文献互助智能选刊最新文献

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-02-04 DOI:10.1111/dom.16222

Malene Svoldgaard Sørensen MSc, Anton Pottegård DMSc, Nanna Elman Andersen PhD, Reimar W. Thomsen PhD, Carina Lundby PhD

{"title":"Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects","authors":"Malene Svoldgaard Sørensen MSc, Anton Pottegård DMSc, Nanna Elman Andersen PhD, Reimar W. Thomsen PhD, Carina Lundby PhD","doi":"10.1111/dom.16222","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Since the launch of semaglutide for weight loss (Wegovy®, SEMA-WL) in late 2022, there has been a huge increase in new users of SEMA-WL. We explored characteristics, treatment expectations and experienced effectiveness and side effects among Danish adults using SEMA-WL.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>A questionnaire-based survey was conducted from September to December 2023 across 29 Danish community pharmacies. During a 10-day period, pharmacies invited consecutive individuals aged ≥18 years redeeming a prescription on SEMA-WL to complete an electronic questionnaire.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 1013 individuals were invited to study participation of which 55% (<i>n</i> = 559) accepted. Users of SEMA-WL were primarily female (78%, <i>n</i> = 434) and middle-aged adults (36–65 years; 76%, <i>n</i> = 423), with a median body mass index of 36 (interquartile range [IQR] 32–40) at treatment initiation. Two in three users had personally asked their general practitioner to initiate treatment (70%, <i>n</i> = 393). Four in ten users had not discussed expected treatment duration with their general practitioner (42%, <i>n</i> = 237), almost half (46%, <i>n</i> = 258) expected treatment for a limited time period, while only 11% (<i>n</i> = 64) expected lifelong treatment. Self-reported median weight loss was 5.3% (IQR 3.2–8.5) for users treated for <3 months, 10% (IQR 8.2–14) for 3–5 months of treatment and 17% (IQR 13–21) for those treated for >5 months. More than half of users (59%, <i>n</i> = 330) had experienced side effects, most commonly nausea (35%, <i>n</i> = 193) and constipation (29%, <i>n</i> = 160).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This study provides valuable insights into the characteristics, treatment expectations and effects experienced by Danish adult users of SEMA-WL.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 4","pages":"2214-2222"},"PeriodicalIF":5.4000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16222","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.16222","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的：自2022年末推出用于减肥的塞马鲁肽（Wegovy®，SEMA-WL）以来，SEMA-WL的新用户大幅增加。我们探讨了使用SEMA-WL的丹麦成年人的特征、治疗期望以及体验到的疗效和副作用：2023 年 9 月至 12 月，我们在丹麦 29 家社区药房进行了问卷调查。在为期 10 天的时间里，药房邀请连续使用 SEMA-WL 兑换处方的年龄≥18 岁的个人填写电子问卷：共有 1013 人受邀参与研究，其中 55%（n = 559）的人接受了邀请。SEMA-WL的使用者主要是女性（78%，n = 434）和中年人（36-65岁；76%，n = 423），开始治疗时的体重指数中位数为36（四分位数间距[IQR] 32-40）。三分之二的使用者曾亲自要求其全科医生启动治疗（70%，n = 393）。十分之四的用户没有与他们的全科医生讨论过预期的治疗时间（42%，n = 237），近一半（46%，n = 258）的用户预期治疗时间有限，而只有 11%（n = 64）的用户预期终身治疗。接受 5 个月治疗的用户自我报告的体重减轻中位数为 5.3%（IQR 3.2-8.5 ）。超过半数的使用者（59%，n = 330）出现过副作用，最常见的是恶心（35%，n = 193）和便秘（29%，n = 160）：这项研究为了解丹麦成人SEMA-WL使用者的特点、治疗期望和效果提供了宝贵的资料。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects

查看原文本刊更多论文

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects

Aims

Since the launch of semaglutide for weight loss (Wegovy®, SEMA-WL) in late 2022, there has been a huge increase in new users of SEMA-WL. We explored characteristics, treatment expectations and experienced effectiveness and side effects among Danish adults using SEMA-WL.

Materials and Methods

A questionnaire-based survey was conducted from September to December 2023 across 29 Danish community pharmacies. During a 10-day period, pharmacies invited consecutive individuals aged ≥18 years redeeming a prescription on SEMA-WL to complete an electronic questionnaire.

Results

A total of 1013 individuals were invited to study participation of which 55% (n = 559) accepted. Users of SEMA-WL were primarily female (78%, n = 434) and middle-aged adults (36–65 years; 76%, n = 423), with a median body mass index of 36 (interquartile range [IQR] 32–40) at treatment initiation. Two in three users had personally asked their general practitioner to initiate treatment (70%, n = 393). Four in ten users had not discussed expected treatment duration with their general practitioner (42%, n = 237), almost half (46%, n = 258) expected treatment for a limited time period, while only 11% (n = 64) expected lifelong treatment. Self-reported median weight loss was 5.3% (IQR 3.2–8.5) for users treated for <3 months, 10% (IQR 8.2–14) for 3–5 months of treatment and 17% (IQR 13–21) for those treated for >5 months. More than half of users (59%, n = 330) had experienced side effects, most commonly nausea (35%, n = 193) and constipation (29%, n = 160).

Conclusions

This study provides valuable insights into the characteristics, treatment expectations and effects experienced by Danish adult users of SEMA-WL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.